CBMX - CombiMatrix Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
7.95
+0.10 (+1.27%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close7.85
Open7.85
Bid7.90 x 100
Ask8.40 x 200
Day's Range7.85 - 8.00
52 Week Range2.15 - 8.20
Volume21,696
Avg. Volume93,624
Market Cap23.36M
Beta1.76
PE Ratio (TTM)-9.06
EPS (TTM)-0.88
Earnings DateMay 4, 2017 - May 8, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.02
Trade prices are not sourced from all markets
  • GlobeNewswire19 hours ago

    CombiMatrix to Present New Data from a Large-Scale Analysis of Genomic Abnormalities Impacting Multiple Stages of Human Growth and Development Starting from Conception through Childhood at the American Society of Human Genetics Annual Meeting

    IRVINE, Calif., Oct. 20, 2017-- CombiMatrix Corporation, a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, announces the presentation ...

  • PR Newswire9 days ago

    SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of CombiMatrix Corporation - CBMX

    NEW YORK , Oct. 12, 2017 /PRNewswire/ --  Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a boutique securities firm headquartered at the Empire State Building in New York ...

  • Invitae Commences Exchange Offer for CombiMatrix Series F Warrants
    PR Newswire15 days ago

    Invitae Commences Exchange Offer for CombiMatrix Series F Warrants

    SAN FRANCISCO, Oct. 6, 2017 /PRNewswire/ -- Invitae Corporation (NVTA), one of the fastest growing genetic information companies, today announced that it has commenced an offer to exchange (the "Exchange Offer") each outstanding Series F warrant (CUSIP No. 20009T147) (the "CombiMatrix Series F Warrants") to acquire one share of common stock of CombiMatrix Corporation ("CombiMatrix") for 0.3056 of a share of common stock, par value $0.0001 per share, of Invitae (the "Invitae Common Stock"). The Exchange Offer will expire at 12:00 midnight, New York City time, on November 13, 2017 (one minute after 11:59 p.m., New York City time, on November 12, 2017), or any other date and time to which Invitae extends the Exchange Offer (such date and time, as it may be extended, the "Expiration Date").

  • GlobeNewswire26 days ago

    CombiMatrix Sets Record Date and Special Stockholders Meeting Date Regarding Proposed Merger with Invitae

    IRVINE, Calif., Sept. 25, 2017-- CombiMatrix Corporation, a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, announced today it ...

  • CombiMatrix Corp. :CBMX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 31, 2017
    Capital Cube2 months ago

    CombiMatrix Corp. :CBMX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 31, 2017

    Categories: Yahoo FinanceGet free summary analysis CombiMatrix Corp. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of CombiMatrix Corp. – Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, NeoGenomics, Inc. and RadNet, Inc. (DGX-US, LH-US, NEO-US and RDNT-US) that have also reported for this period. Highlights ... Read more (Read more...)

  • GlobeNewswire3 months ago

    CombiMatrix Corporation Reports Second Quarter 2017 Financial and Operating Results

    IRVINE, Calif., Aug. 03, 2017-- CombiMatrix Corporation, a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, announces financial ...

  • ACCESSWIRE3 months ago

    Today's Research Reports on Trending Tickers: CombiMatrix Corporation and Puma Biotechnology

    NEW YORK, NY / ACCESSWIRE / August 2, 2017 / A strong earnings season continued to push U.S. markets higher Tuesday. The Dow Jones Industrial Average closed at a new record high for the 5th consecutive ...

  • CombiMatrix shares jump on buyout news
    Investing.com3 months ago

    CombiMatrix shares jump on buyout news

    Investing.com - Shares of CombiMatrix Corp (NASDAQ:CBMX) rallied on Tuesday and were up about 40% on the home stretch to the closing bell with investors cheering a proposed merger of the company with InVitae Corp (NYSE:NVTA)

  • GlobeNewswire3 months ago

    CombiMatrix Enters Into Merger Agreement with Invitae Corporation to be Acquired for $33 Million in Invitae Common Stock

    $27 million offered to holders of CombiMatrix Common Stock subject to certain adjustments. $6 million offered to holders of CombiMatrix Series F Warrants. IRVINE, Calif., July 31, 2017-- CombiMatrix Corporation, ...

  • Invitae Acquiring Good Start Genetics and CombiMatrix, Adding Comprehensive Reproductive Health Capabilities to Serve Every Stage of Life
    PR Newswire3 months ago

    Invitae Acquiring Good Start Genetics and CombiMatrix, Adding Comprehensive Reproductive Health Capabilities to Serve Every Stage of Life

    SAN FRANCISCO, July 31, 2017 /PRNewswire/ -- Invitae Corporation (NVTA), one of the fastest growing genetic information companies, today announced two acquisitions to establish a leading position in family health genetic information services. Invitae has entered into a definitive agreement to acquire privately held Good Start Genetics, a molecular diagnostics company focused on preimplantation and carrier screening for inherited disorders.

  • CombiMatrix Corp. :CBMX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 29, 2017
    Capital Cube5 months ago

    CombiMatrix Corp. :CBMX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 29, 2017

    Categories: Yahoo FinanceGet free summary analysis CombiMatrix Corp. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of CombiMatrix Corp. – Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, NeoGenomics, Inc., RadNet, Inc. and Transgenomic, Inc. (DGX-US, LH-US, NEO-US, RDNT-US and TBIO-US) that have also reported for ... Read more (Read more...)

  • Accesswire5 months ago

    Today's Research Reports on Stocks to Watch: CombiMatrix and Eyegate Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / May 8, 2017 / Positive economic data and continued strength in corporate earnings pushed U.S. markets into the green Friday. The Dow Jones Industrial Average gained 0.26 percent ...

  • Thomson Reuters StreetEvents6 months ago

    Edited Transcript of CBMX earnings conference call or presentation 4-May-17 8:30pm GMT

    Q1 2017 CombiMatrix Corp Earnings Call

  • PR Newswire6 months ago

    SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating CombiMatrix Corporation for Potential Breaches Of Fiduciary Duty By Its Board of Directors

    NEW YORK, May 2, 2017 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of CombiMatrix Corporation (CBMX). You may also contact Robert H. Lefkowitz, Esq. Purcell Julie & Lefkowitz LLP is a law firm exclusively committed to representing shareholders nationwide who are victims of securities fraud, breaches of fiduciary duty and other types of corporate misconduct.

  • Accesswire7 months ago

    CombiMatrix and Vertex Pharmaceuticals Make Gains

    NEW YORK, NY / ACCESSWIRE / March 30, 2017 / CombiMatrix and Vertex Pharmaceuticals have made investors optimistic about the future of their companies as both stocks find broader markets for their products. ...

  • CombiMatrix Corp. :CBMX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017
    Capital Cube7 months ago

    CombiMatrix Corp. :CBMX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017

    Categories: Yahoo Finance Get free summary analysis CombiMatrix Corp. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of CombiMatrix Corp. – Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Enzo Biochem, Inc., NeoGenomics, Inc. and RadNet, Inc. (DGX-US, LH-US, ENZ-US, NEO-US and RDNT-US) that have also reported ... Read more (Read more...)

  • CombiMatrix Corp. :CBMX-US: Earnings Analysis: 2016 By the Numbers : March 13, 2017
    Capital Cube7 months ago

    CombiMatrix Corp. :CBMX-US: Earnings Analysis: 2016 By the Numbers : March 13, 2017

    Categories: Yahoo Finance Get free summary analysis CombiMatrix Corp. reports financial results for the year ended December 31, 2016. We analyze the earnings along side the following peers of CombiMatrix Corp. – Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings and NeoGenomics, Inc. (DGX-US, LH-US and NEO-US) that have also reported for this period. Highlights Gross margins widened ... Read more (Read more...)

  • Zacks Small Cap Research8 months ago

    CBMX: Q4 Records On Almost Every Measure

    Some things only change for the better.  That continues to be the story with CombiMatrix’s (CBMX) operational and financial results.  The company reported Q4 earnings last week which set new records on revenue, gross margin, profitability and cash collections.  The strong financial performance was largely the product of their bread-and-butter reproductive health microarray portfolio (i.e. As we have noted in the past, the company’s financial performance is a direct result of execution of management’s strategy.  CBMX has been actively engaged in their fate by targeting geographic areas with favorable reimbursement, sponsoring or otherwise supporting evidence-based studies, communicating with payers and optimizing their product portfolio to include cash-pay products.  The company’s recent implementation of a new compensation model and other efficiency initiatives has resulted in a rapid and substantial shedding of expenses.  And favorable changes in payers’ coverage decisions, CBMX’s investments in billing and collections resources, sales force training and their deft updates to their product portfolio have contributed to margin expansion and greatly improved cash collections.

  • Zacks Small Cap Research8 months ago

    CBMX:Expect Record Revenue, Profit in 2017 On Strong Fundamentals

    Through the first nine months of 2016 CombiMatrix’s (CBMX) revenue is up 26%, gross margin is 800 basis points wider, operating loss is 28% lower and EBITDA loss is improved by almost 38% as compared to the same period in 2015.  As we have recently noted, we characterize the improved financial performance as ‘high quality’ and what reasonably could be expected to be replicable given that these are the products of CombiMatrix’s direct efforts and/or favorable changes in industry fundamentals. CBMX has been actively engaged in their fate by targeting geographic areas with favorable reimbursement, sponsoring or otherwise supporting evidence-based studies, communicating with payers and optimizing their product portfolio to include cash-pay products.  The company’s recent implementation of a new compensation model and other efficiency initiatives has resulted in a rapid and substantial shedding of expenses.  And favorable changes in payers’ coverage decisions, CBMX’s investments in billing and collections resources and their deft updates to their product portfolio have contributed to margin expansion and greatly improved cash collections.